TP53I3

Summary

TP53I3 (tumor protein p53 inducible protein 3, HGNC:19373) is a protein-coding gene on chromosome 2p23.3, encoding Quinone oxidoreductase PIG3 (Q53FA7). NADPH:quinone reductase which expression is induced by p53/TP53 and is involved in both the DNA damage response through homologous recombination repair, and p53-mediated apoptosis.

The protein encoded by this gene is similar to oxidoreductases, which are enzymes involved in cellular responses to oxidative stresses and irradiation. This gene is induced by the tumor suppressor p53 and is thought to be involved in p53-mediated cell death. It contains a p53 consensus binding site in its promoter region and a downstream pentanucleotide microsatellite sequence. P53 has been shown to transcriptionally activate this gene by interacting with the downstream pentanucleotide microsatellite sequence. The microsatellite is polymorphic, with a varying number of pentanucleotide repeats directly correlated with the extent of transcriptional activation by p53. It has been suggested that the microsatellite polymorphism may be associated with differential susceptibility to cancer. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 9540 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 4 total
• MANE Select transcript: NM_004881

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19373
Approved symbol	TP53I3
Name	tumor protein p53 inducible protein 3
Location	2p23.3
Locus type	gene with protein product
Status	Approved
Aliases	PIG3
Ensembl gene	ENSG00000115129
Ensembl biotype	protein_coding
OMIM	605171
Entrez	9540

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000238721, ENST00000335934, ENST00000407482, ENST00000413037, ENST00000417886, ENST00000470636, ENST00000861137, ENST00000861138, ENST00000923540

RefSeq mRNA: 3 — MANE Select: NM_004881 NM_001206802, NM_004881, NM_147184

CCDS: CCDS1708, CCDS56112

Canonical transcript exons

ENST00000238721 — 5 exons

Exon	Start	End
ENSE00000721466	24079444	24079640
ENSE00000721478	24082885	24083152
ENSE00001374637	24084189	24084834
ENSE00001743570	24077433	24077761
ENSE00003613580	24080819	24081031

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 98.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.0409 / max 210.0351, expressed in 1749 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
27310	8.1784	1571
27313	3.8191	1411
27312	2.5378	1174
27309	2.5021	1213
27308	1.9991	1076
27311	1.6079	980
27314	0.3217	86
27315	0.0748	8

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.37	gold quality
ileal mucosa	UBERON:0000331	96.45	gold quality
esophagus mucosa	UBERON:0002469	96.43	gold quality
pancreatic ductal cell	CL:0002079	95.47	gold quality
mucosa of transverse colon	UBERON:0004991	95.43	gold quality
esophagus squamous epithelium	UBERON:0006920	95.30	gold quality
epithelium of esophagus	UBERON:0001976	95.07	gold quality
metanephros cortex	UBERON:0010533	94.60	gold quality
duodenum	UBERON:0002114	93.79	gold quality
transverse colon	UBERON:0001157	93.78	gold quality
cervix squamous epithelium	UBERON:0006922	93.65	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.62	gold quality
rectum	UBERON:0001052	93.25	gold quality
body of pancreas	UBERON:0001150	92.69	gold quality
cervix epithelium	UBERON:0004801	92.61	gold quality
small intestine	UBERON:0002108	92.49	gold quality
vagina	UBERON:0000996	92.31	gold quality
squamous epithelium	UBERON:0006914	92.00	gold quality
colonic mucosa	UBERON:0000317	91.68	gold quality
left testis	UBERON:0004533	91.51	gold quality
gall bladder	UBERON:0002110	91.43	gold quality
upper lobe of left lung	UBERON:0008952	91.16	gold quality
upper lobe of lung	UBERON:0008948	91.07	gold quality
tibial nerve	UBERON:0001323	91.04	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	90.91	gold quality
right testis	UBERON:0004534	90.85	gold quality
intestine	UBERON:0000160	90.51	gold quality
mucosa of sigmoid colon	UBERON:0004993	90.50	gold quality
nasal cavity epithelium	UBERON:0005384	90.43	gold quality
jejunal mucosa	UBERON:0000399	90.35	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	53.84
E-MTAB-7037	no	243.09
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KDM4B, TP53, TP73

miRNA regulators (miRDB)

9 targeting TP53I3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-670-3P	99.03	68.88	2404
HSA-MIR-6794-3P	98.76	66.99	894
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-5691	98.23	67.02	1335
HSA-MIR-6805-3P	98.23	67.02	1334
HSA-MIR-4421	97.99	64.89	701
HSA-MIR-5699-3P	97.81	65.00	861
HSA-MIR-214-5P	97.34	66.50	617
HSA-MIR-6735-3P	96.10	63.81	600

Literature-anchored findings (GeneRIF, showing 17)

• p53 activity and PIG3 gene function are uncoupled by UV-dependent alternative splicing through rapid proteolytic degradation (PMID:15067011)
• suppression of p53-C277Y by RNAi reduced pig3 promoter activity, RNA, and protein expression (PMID:15192123)
• numerous factors contribute to the normal alternative splicing of PIG3 exon 4 and UV-inducible increases in this process require that the splicing of this exon be maintained in a sufficiently weakened state under normal conditi (PMID:18801469)
• PIG3 action is through oxidative stress produced by its enzymatic activity and provides essential knowledge for eventual control of apoptosis. (PMID:19349281)
• Results suggest that PIG3 is a critical component of the DNA damage response pathway and has a direct role in the transmission of the DNA damage signal from damaged DNA to the intra-S and G2/M checkpoint machinery. (PMID:20023697)
• certain p53 mutatants activate PIG3, whereas the result of our study show increased full-length transcript expression in tumor counterparts (PMID:20603616)
• a novel signaling pathway of GPx3-PIG3 in the regulation of cell death in prostate cancer. (PMID:22461624)
• study provides evidence that the variant genotypes of (TGYCC)n repeats in the PIG3 promoter are functional and associated with risk of squamous cell carcinoma of the head and neck in a non-Hispanic white population (PMID:23241165)
• prohibitin and prohibiton (PHB2) contribute to PIG3-mediated apoptosis by binding to the PIG3 promoter (TGYCC)15 motif (PMID:24388982)
• The results suggested that PIG3 plays an oncogenic role in PTC via the regulation of the PI3K/AKT/PTEN pathway and support the exploration of PIG3 as a novel biomarker for patients with papillary thyroid carcinoma (PMID:26133772)
• PIG3, which functions in DNA damage repair, uses an unexpected catalytic mechanism to suppress Rho-ROCK activity and impair tumor invasion in vivo. This regulation was suppressed by antioxidants. (PMID:26464464)
• Data indicate that knockdown of p53-induced gene 3 (PIG-3) expression by small interfering RNA (siRNA) treatment can inhibit the generation of reactive oxygen species (ROS). (PMID:26472723)
• Data suggest that PIG3 was involved in HIF-1alpha regulation, and indicate a signaling pathway of PIG3/HIF-1alpha in the regulation of cell migration in renal cell carcinoma. (PMID:27029070)
• Results revealed that PIG3 expression levels positively correlated with poor prognosis of non-small cell lung cancer (NSCLC) patients and indicate that PIG3 promotes NSCLC progression. (PMID:28259183)
• our data suggest that high expression of p53-inducible gene 3 is significant for glioblastoma inhibition and p53-inducible gene 3 independently indicates good prognosis in patients, which might be a novel prognostic biomarker or potential therapeutic target in glioblastoma. (PMID:28351326)
• Study found that PIG3 expression was positively associated with lymph node metastasis from lung adenocarcinoma (LUAD) but not from lung squamous cell carcinoma (LUSC). Further data revealed a role for PIG3 in inducing LUAD metastasis, and its role as a new FAK regulator, suggesting that it could be considered as a novel prognostic biomarker. (PMID:30281878)
• expression of PIG3 is frequently reduced in gastric cancer (GC) tissue, and PIG3 suppressed human GC growth through p53- mediated apoptosis; PIG3 may act as a potential diagnostic marker and a potential therapeutic target of GC (PMID:30334411)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	TP53I3	ENSDARG00000106158
caenorhabditis_elegans		WBGENE00010790
caenorhabditis_elegans		WBGENE00010791
caenorhabditis_elegans		WBGENE00017060

Paralogs (17): PTGR1 (ENSG00000106853), VAT1 (ENSG00000108828), MECR (ENSG00000116353), CRYZ (ENSG00000116791), RTN4IP1 (ENSG00000130347), PTGR2 (ENSG00000140043), SORD (ENSG00000140263), VAT1L (ENSG00000171724), ADH6 (ENSG00000172955), PTGR3 (ENSG00000180011), ADH1A (ENSG00000187758), ADH7 (ENSG00000196344), ADH1B (ENSG00000196616), ADH5 (ENSG00000197894), ADH4 (ENSG00000198099), CRYZL1 (ENSG00000205758), ADH1C (ENSG00000248144)

Protein

Protein identifiers

Quinone oxidoreductase PIG3 — Q53FA7 (reviewed: Q53FA7)

Alternative names: NADPH:quinone reductase PIG3, Tumor protein p53-inducible protein 3, p53-induced gene 3 protein

All UniProt accessions (2): Q53FA7, H7BZH6

UniProt curated annotations — full annotation on UniProt →

Function. NADPH:quinone reductase which expression is induced by p53/TP53 and is involved in both the DNA damage response through homologous recombination repair, and p53-mediated apoptosis. Catalyzes the NADPH-dependent reduction of quinones, exhibiting a low enzymatic activity with beta-naphthoquinones and a strong preference for the ortho-quinone isomer (1,2-beta-naphthoquinone) over the para isomer (1,4-beta-naphthoquinone). Also displays a low reductase activity for non-quinone compounds such as diamine and 2,6-dichloroindophenol (in vitro). The reduction of 1,2-naphthoquinone concurrently generates reactive oxygen species (ROS), which may trigger apoptosis downstream of p53/TP53.

Subunit / interactions. Homodimer.

Induction. Isoform 1 and isoform 2 are both activated by oxorubicin, etoposide and ionizing radiation. Isoform 2 is highly activated by UV radiation.

Miscellaneous. Major isoform under normal light conditions. Major isoform under UV light exposure. Undergoes rapid proteolytic degradation by the proteasome.

Similarity. Belongs to the zinc-containing alcohol dehydrogenase family. Quinone oxidoreductase subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q53FA7-1	1	yes
Q53FA7-2	2, PIG3AS

RefSeq proteins (3): NP_001193731, NP_004872, NP_671713 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011032	GroES-like_sf	Homologous_superfamily
IPR013149	ADH-like_C	Domain
IPR013154	ADH-like_N	Domain
IPR014189	Quinone_OxRdtase_PIG3	Family
IPR020843	ER	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily

Pfam: PF00107, PF08240

Catalyzed reactions (Rhea), 2 shown:

• 2 a quinone + NADPH + H(+) = 2 a 1,4-benzosemiquinone + NADP(+) (RHEA:14269)
• 2 1,2-naphthoquinone + NADPH + H(+) = 2 1,2-naphthosemiquinone + NADP(+) (RHEA:85243)

UniProt features (57 total): strand 18, helix 15, binding site 8, sequence variant 3, mutagenesis site 3, sequence conflict 3, turn 3, splice variant 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2J8Z	X-RAY DIFFRACTION	2.5
2OBY	X-RAY DIFFRACTION	3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53FA7-F1	97.06	0.98

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 41; 152; 173; 177; 192; 264; 266; 322

Post-translational modifications (1): 1

Mutagenesis-validated functional residues (3):

Position	Phenotype
51	loss of nadph:quinone reductase activity.
51	increased nadph:quinone reductase activity.
151	loss of nadph:quinone reductase activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain

MSigDB gene sets: 112 (showing top): MODULE_93, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, KAUFFMANN_DNA_REPAIR_GENES, PATIL_LIVER_CANCER, GOBP_REACTIVE_OXYGEN_SPECIES_BIOSYNTHETIC_PROCESS, BROWNE_HCMV_INFECTION_14HR_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP, BROWNE_HCMV_INFECTION_24HR_DN, PID_P53_DOWNSTREAM_PATHWAY, PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NAD_P_H, KUMAMOTO_RESPONSE_TO_NUTLIN_3A_UP, SCHAVOLT_TARGETS_OF_TP53_AND_TP63, IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP

GO Biological Process (3): apoptotic process (GO:0006915), reactive oxygen species biosynthetic process (GO:1903409), NADP+ metabolic process (GO:0006739)

GO Molecular Function (5): quinone reductase (NADPH) activity (GO:0003960), quinone binding (GO:0048038), NADPH binding (GO:0070402), oxidoreductase activity (GO:0016491), protein homodimerization activity (GO:0042803)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
TP53 Regulates Transcription of Cell Death Genes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
biosynthetic process	1
reactive oxygen species metabolic process	1
purine nucleotide metabolic process	1
nicotinamide nucleotide metabolic process	1
NADPH dehydrogenase activity	1
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor	1
small molecule binding	1
anion binding	1
NADP binding	1
catalytic activity	1
identical protein binding	1
protein dimerization activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1698 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TP53I3	SESN1	Q9Y6P5	642
TP53I3	TP53	P04637	636
TP53I3	FDXR	P22570	593
TP53I3	TCHP	Q9BT92	557
TP53I3	CDKN1A	P38936	505
TP53I3	SESN3	P58005	498
TP53I3	GADD45A	P24522	489
TP53I3	BBC3	Q96PG8	488
TP53I3	RRM2B	Q7LG56	484
TP53I3	DRAM1	Q8N682	459
TP53I3	PIDD1	Q9HB75	457
TP53I3	TRIAP1	O43715	455
TP53I3	ZMAT3	Q9HA38	445
TP53I3	MDM2	Q00987	438
TP53I3	CMIP	Q8IY22	427

IntAct

10 interactions, top by confidence:

A	B	Type	Score
	FER1L5	psi-mi:“MI:0915”(physical association)	0.400
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350
	MYO1C	psi-mi:“MI:0914”(association)	0.350
TP53I3	UNC119	psi-mi:“MI:0915”(physical association)	0.000
TP53I3	EEF1G	psi-mi:“MI:0915”(physical association)	0.000
TP53I3	UBR1	psi-mi:“MI:0915”(physical association)	0.000
TP53I3	FUNDC2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): HMBS (Co-fractionation), TP53I3 (Two-hybrid), TP53I3 (Affinity Capture-Western), GPX3 (Affinity Capture-Western), GPX3 (Reconstituted Complex), MDM2 (Affinity Capture-Western), MDM2 (Reconstituted Complex), FUNDC2 (Two-hybrid), EEF1G (Two-hybrid), UBR1 (Two-hybrid), UNC119 (Two-hybrid), TP53I3 (Co-fractionation), TP53I3 (Co-fractionation), MAP4K5 (Co-fractionation), TP53I3 (Affinity Capture-MS)

ESM2 similar proteins: A0A9E7LUR3, A9CES3, B2NI93, C6BUS3, E5AE42, N4WR35, O06012, O32264, O34815, O35017, O46650, O74822, O94564, P0A9S3, P0A9S4, P0DXJ1, P25145, P25377, P38105, P38230, P39462, P50381, P63475, P77316, P99173, Q02912, Q06004, Q32L99, Q4J781, Q53FA7, Q57517, Q59545, Q59I44, Q5BK81, Q5HE19, Q5HM44, Q5R806, Q6G7C8, Q6GEP3, Q6WAU0

Diamond homologs: A0A089FS99, A0A0C6DWS6, A0A0E0RXA7, A0A0E3U2K2, A0A0E4FKF7, A0A0F7GFI5, A0A0F9XJT1, A0A0L1JEX1, A0A1L7TY28, A0A1P8VF85, A0A1V6PAP3, A0A1W5T1Y4, A0A2L0P0L5, A0A2Z5XAK4, A0A3Q9U4Z5, A0A411KUQ4, A0A411KZZ8, A0A481WQL4, A0A482N9T9, A0A4P8W733, A0A6F8RQ72, A0A7L8UWS6, A0A7L9EZZ4, A0A8F4NUY3, A0A8F4S717, A0A8K1AWG4, A0JJU0, A1CLZ2, A2QQU5, A2QTF1, B1GVX6, B8NJH1, D7UPN2, G0REX7, G2Q9A7, G3JUI7, G3XMC6, G4MVZ3, G4MWB1, J5JCC9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
KDM4B	“down-regulates quantity by repression”	TP53I3	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

4 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1012 predictions. Top by Δscore:

Variant	Effect	Δscore
2:24077762:C:CC	acceptor_gain	1.0000
2:24080814:TTTA:T	donor_loss	1.0000
2:24080815:TTAC:T	donor_loss	1.0000
2:24080816:TA:T	donor_loss	1.0000
2:24080817:ACCTT:A	donor_loss	1.0000
2:24080818:C:CA	donor_loss	1.0000
2:24085052:T:TA	donor_gain	1.0000
2:24077760:TA:T	acceptor_gain	0.9900
2:24081028:TTTC:T	acceptor_gain	0.9900
2:24081029:TTC:T	acceptor_gain	0.9900
2:24081030:TC:T	acceptor_gain	0.9900
2:24081031:CC:C	acceptor_gain	0.9900
2:24081032:C:CC	acceptor_gain	0.9900
2:24081032:C:CG	acceptor_loss	0.9900
2:24081038:C:CT	acceptor_gain	0.9900
2:24081039:A:T	acceptor_gain	0.9900
2:24082999:A:AC	donor_gain	0.9900
2:24083000:C:CC	donor_gain	0.9900
2:24083050:T:TA	donor_gain	0.9900
2:24084970:T:TA	donor_gain	0.9900
2:24085004:G:C	donor_gain	0.9900
2:24077757:TTGTA:T	acceptor_gain	0.9800
2:24077758:TGTA:T	acceptor_gain	0.9800
2:24077758:TGTAC:T	acceptor_gain	0.9800
2:24077759:GTAC:G	acceptor_loss	0.9800
2:24077761:ACTA:A	acceptor_loss	0.9800
2:24077762:C:T	acceptor_loss	0.9800
2:24077763:T:G	acceptor_loss	0.9800
2:24079483:T:TA	donor_gain	0.9800
2:24079645:C:CT	acceptor_gain	0.9800

AlphaMissense

2130 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:24082918:A:G	W125R	0.985
2:24082918:A:T	W125R	0.985
2:24079557:A:G	W235R	0.984
2:24079557:A:T	W235R	0.984
2:24079468:A:C	S264R	0.983
2:24079468:A:T	S264R	0.983
2:24079470:T:G	S264R	0.983
2:24080959:A:G	L160P	0.982
2:24079617:C:G	D215H	0.980
2:24084207:G:C	N40K	0.979
2:24084207:G:T	N40K	0.979
2:24083100:T:A	E64V	0.978
2:24083091:C:T	G67E	0.977
2:24077756:C:A	K274N	0.976
2:24077756:C:G	K274N	0.976
2:24079616:T:A	D215V	0.974
2:24077607:C:A	G324V	0.973
2:24080971:G:T	A156D	0.973
2:24083005:C:G	A96P	0.973
2:24084232:A:G	L32P	0.973
2:24077607:C:T	G324D	0.972
2:24081004:A:G	L145P	0.972
2:24079625:A:G	L212P	0.970
2:24080985:A:C	S151R	0.970
2:24080985:A:T	S151R	0.970
2:24080987:T:G	S151R	0.970
2:24082922:C:A	E123D	0.970
2:24082922:C:G	E123D	0.970
2:24082939:C:G	A118P	0.970
2:24084200:C:G	D43H	0.970

dbSNP variants (sampled 300 via entrez): RS1000012539 (2:24081068 A>G), RS1000205395 (2:24084410 A>G), RS1000369495 (2:24080459 C>T), RS1001212661 (2:24086198 G>A), RS1001264845 (2:24086834 C>G), RS1001309445 (2:24086488 C>T), RS1001425783 (2:24079785 T>G), RS1001876404 (2:24085679 C>T), RS1002328807 (2:24079701 A>T), RS1002359869 (2:24079350 G>A,C,T), RS1003332155 (2:24078005 G>A), RS1003467721 (2:24084611 G>A), RS1003556007 (2:24084704 TC>T,TCC), RS1003650858 (2:24084978 G>A,T), RS1003810846 (2:24078469 C>T)

Disease associations

OMIM: gene MIM:605171 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

105 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cisplatin	increases expression, increases reaction, decreases expression, affects response to substance	8
Benzo(a)pyrene	affects cotreatment, increases expression	7
Fluorouracil	affects response to substance, affects reaction, increases reaction, increases expression	7
sodium arsenite	decreases expression, increases expression	5
Doxorubicin	affects expression, increases expression	5
Aflatoxin B1	affects expression, increases expression, affects reaction	5
nutlin 3	affects cotreatment, increases expression, increases secretion	3
Quercetin	increases expression	3
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	3
Cadmium Chloride	decreases expression, increases expression	3
kaempferol	increases expression	2
sodium arsenate	decreases expression	2
cobaltous chloride	decreases expression	2
chrysin	increases expression	2
monomethylarsonous acid	decreases expression, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	2
Estradiol	affects binding, increases expression, affects cotreatment	2
Formaldehyde	decreases expression, increases expression	2
Methotrexate	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Valproic Acid	affects expression, decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	2
Cyclosporine	decreases expression	2
Luteolin	increases expression	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, increases expression	1
chloroacetaldehyde	affects expression	1
triphenyl phosphate	affects expression	1
benzo(b)fluoranthene	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2JD	Abcam HeLa TP53I3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.